Despite the often dismal mood over the weekend, the Asco conference provided rich pickings for some biotech investors.
ILT3 blockade shows no monotherapy activity while a combo runs into toxicity issues, but Merck presses on.
On the eve of Asco two deals show that the current biotech market malaise might be focusing some chief executives’ minds.
June will see adcoms aplenty, with Bluebird, Acadia, and the Covid vaccine makers Novavax, Pfizer/Biontech and Moderna all facing FDA committees.
But breaking Pfizer and Merck’s duopoly will not be easy.
New extended consensus forecasts from Evaluate Pharma show Roche edged out of first place by Abbvie as new blood replaces Humira.